Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181271 · ClinicalTrials.gov registry record · Phase 2
Tandem Auto-Allo Transplant for Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01181271: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01181271 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01181271, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.
Primary Outcome
Successful donor stem cell engraftment is defined as when ≥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation.
Interventions
- DRUG Busulfan (conditioning for AUTO transplant)
- DRUG Etoposide (conditioning for AUTO transplant)
- DRUG Cyclophosphamide (conditioning for AUTO transplant)
- DRUG Mesna (prior to AUTO transplant)
- OTHER autologous (auto) peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
What the finished NCT01181271 record still lists
NCT01181271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Busulfan (conditioning for AUTO transplant) is the first listed.
NCT01181271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01181271 about?
NCT01181271 is a clinical study titled "Tandem Auto-Allo Transplant for Lymphoma". Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will as...
What is the current status of trial NCT01181271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01181271?
The interventions under investigation include: Busulfan (conditioning for AUTO transplant) (DRUG), Etoposide (conditioning for AUTO transplant) (DRUG), Cyclophosphamide (conditioning for AUTO transplant) (DRUG), Mesna (prior to AUTO transplant) (DRUG), autologous (auto) peripheral blood stem cell transplantation (OTHER).
Who is sponsoring clinical trial NCT01181271?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01181271's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia